Graves Ophthalmopathy - 22 Studies Found

Completed : Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy
: Thyroid Associated Ophthalmopathy
: 2016-04-24
: Device: Optical Coherence Tomography All groups were measured by optical coherence tomography.
Active, not recruiting : Teprotumumab Treatment in Patients With Active Thyroid Eye Disease
:
  • Thyroid Associated Ophthalmopathies
  • Thyro
    : 2013-05-02
    :
    • Drug: teprotumumab 10mg/kg fir
Not yet recruiting : The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease
: Thyroid Eye Disease
: 2015-04-11
:
  • Drug: Methylprednisolone + ASTED

Recruiting : Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease
: Thyroid Eye Disease
: 2012-10-06
:
  • Drug: Hyaluronic Acid Gel injection

Not yet recruiting : The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)
: Thyroid Eye Disease
: 2015-03-07
:
  • Drug: ASTED A tablet of ASTED

Recruiting : Celecoxib for Thyroid Eye Disease
: Thyroid Eye Disease
: 2016-07-20
:
  • Drug: Celecoxib celecoxib 100m
Recruiting : B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
: Thyroid Eye Disease
: 2014-12-08
Completed : Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy
:
  • Graves' Dysthyroid Ophthalmopathy
  • Thyroid Related Orbitopathy : 2007-01-17
    : Drug: Rituximab
Completed : Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease
: Thyroid Eye Disease
: 2013-02-21
: Device: SENSIMED Triggerfish Other Name: Contact lens sensor intented to continuously record IOP pattern
Terminated : Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
: Thyroid-Associated Ophthalmopathy
: 2006-02-07
: Drug: Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
<<< Previous | Next >>>